DK1140931T3 - 5HT1-antagonister til antidepressiv behandling - Google Patents

5HT1-antagonister til antidepressiv behandling

Info

Publication number
DK1140931T3
DK1140931T3 DK99951040T DK99951040T DK1140931T3 DK 1140931 T3 DK1140931 T3 DK 1140931T3 DK 99951040 T DK99951040 T DK 99951040T DK 99951040 T DK99951040 T DK 99951040T DK 1140931 T3 DK1140931 T3 DK 1140931T3
Authority
DK
Denmark
Prior art keywords
antagonists
antidepressant therapy
antidepressant
therapy
Prior art date
Application number
DK99951040T
Other languages
Danish (da)
English (en)
Inventor
Gene Michael Bright
Kishor Amratlal Desai
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1140931T3 publication Critical patent/DK1140931T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99951040T 1998-12-28 1999-11-03 5HT1-antagonister til antidepressiv behandling DK1140931T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11395798P 1998-12-28 1998-12-28
PCT/IB1999/001772 WO2000039128A1 (en) 1998-12-28 1999-11-03 5ht1 antagonists for antidepressant therapy

Publications (1)

Publication Number Publication Date
DK1140931T3 true DK1140931T3 (da) 2004-04-19

Family

ID=22352526

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99951040T DK1140931T3 (da) 1998-12-28 1999-11-03 5HT1-antagonister til antidepressiv behandling

Country Status (43)

Country Link
US (1) US6525196B1 (id)
EP (1) EP1140931B1 (id)
JP (1) JP2002533463A (id)
KR (1) KR100417506B1 (id)
CN (1) CN1332740A (id)
AP (1) AP2001002188A0 (id)
AR (1) AR024840A1 (id)
AT (1) ATE260278T1 (id)
AU (1) AU761711B2 (id)
BG (1) BG105710A (id)
BR (1) BR9916807A (id)
CA (1) CA2356985C (id)
CO (1) CO5150179A1 (id)
CR (1) CR6398A (id)
CZ (1) CZ291163B6 (id)
DE (1) DE69915113T2 (id)
DK (1) DK1140931T3 (id)
DZ (1) DZ2933A1 (id)
EA (1) EA003099B1 (id)
EE (1) EE04439B1 (id)
ES (1) ES2214892T3 (id)
GE (1) GEP20043227B (id)
GT (1) GT199900224A (id)
HR (1) HRP20010488A2 (id)
HU (1) HUP0104852A3 (id)
ID (1) ID30117A (id)
IL (1) IL143385A0 (id)
IS (1) IS5951A (id)
MA (1) MA26706A1 (id)
NO (1) NO20013215L (id)
NZ (1) NZ511964A (id)
OA (1) OA11742A (id)
PA (1) PA8486701A1 (id)
PE (1) PE20001234A1 (id)
PT (1) PT1140931E (id)
SK (1) SK9002001A3 (id)
TN (1) TNSN99218A1 (id)
TR (1) TR200101979T2 (id)
TW (1) TW523514B (id)
UA (1) UA62015C2 (id)
WO (1) WO2000039128A1 (id)
YU (1) YU44301A (id)
ZA (1) ZA200105041B (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855729B2 (en) * 2001-02-20 2005-02-15 Timothy G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
WO2004081007A1 (en) 2003-03-12 2004-09-23 Pfizer Products Inc. Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
CA2555172A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
WO2006027692A2 (en) * 2004-09-10 2006-03-16 Pfizer Products Inc. Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives
US20080318926A1 (en) * 2004-09-10 2008-12-25 Pfizer Inc Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2021127391A1 (en) * 2019-12-20 2021-06-24 The Jackson Laboratory Molecular targets for addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
US5756496A (en) * 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
CA2288662A1 (en) * 1997-04-18 1998-11-12 Smithkline Beecham P.L.C. Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity
IT1293807B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1

Also Published As

Publication number Publication date
GEP20043227B (en) 2004-04-26
ATE260278T1 (de) 2004-03-15
PE20001234A1 (es) 2000-11-07
EA003099B1 (ru) 2002-12-26
YU44301A (sh) 2004-07-15
GT199900224A (es) 2001-06-15
MA26706A1 (fr) 2004-12-20
NZ511964A (en) 2003-08-29
CA2356985A1 (en) 2000-07-06
CA2356985C (en) 2006-08-08
NO20013215D0 (no) 2001-06-27
BG105710A (en) 2002-02-28
CZ291163B6 (cs) 2003-01-15
EA200100517A1 (ru) 2001-12-24
DE69915113T2 (de) 2004-08-26
TW523514B (en) 2003-03-11
US6525196B1 (en) 2003-02-25
HUP0104852A3 (en) 2002-12-28
NO20013215L (no) 2001-08-27
AU6361499A (en) 2000-07-31
DZ2933A1 (fr) 2004-03-15
AU761711B2 (en) 2003-06-05
KR100417506B1 (ko) 2004-02-05
CR6398A (es) 2004-03-24
KR20010092455A (ko) 2001-10-25
OA11742A (en) 2005-05-13
HUP0104852A2 (hu) 2002-05-29
HRP20010488A2 (en) 2002-08-31
AR024840A1 (es) 2002-10-30
BR9916807A (pt) 2001-10-23
WO2000039128A1 (en) 2000-07-06
EP1140931A1 (en) 2001-10-10
AP2001002188A0 (en) 2001-06-30
JP2002533463A (ja) 2002-10-08
PT1140931E (pt) 2004-05-31
ID30117A (id) 2001-11-08
EE04439B1 (et) 2005-02-15
CN1332740A (zh) 2002-01-23
TNSN99218A1 (fr) 2005-11-10
ZA200105041B (en) 2002-06-20
EE200100346A (et) 2002-12-16
CZ20012386A3 (cs) 2002-02-13
PA8486701A1 (es) 2000-09-29
DE69915113D1 (de) 2004-04-01
IL143385A0 (en) 2002-04-21
ES2214892T3 (es) 2004-09-16
CO5150179A1 (es) 2002-04-29
EP1140931B1 (en) 2004-02-25
TR200101979T2 (tr) 2001-12-21
SK9002001A3 (en) 2002-04-04
UA62015C2 (en) 2003-12-15
IS5951A (is) 2001-05-22

Similar Documents

Publication Publication Date Title
NO20003640D0 (no) Ny doseringsform
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
ID27841A (id) Turunan-turunan biaril terapeutik
FI4209U1 (fi) Uusia yhdisteitä
NO992692D0 (no) Nefadozon doseringsform
NO981305D0 (no) Utblåsningssikring
EE200000171A (et) Uued NPY antagonistid
DK1140931T3 (da) 5HT1-antagonister til antidepressiv behandling
ID26223A (id) Antagonis reseptor vitronektin
ID26086A (id) Ligan-ligan reseptor 5ht1 azabisiklik
NO20003694D0 (no) VLA-4 antagonister
ID27845A (id) Turunan tetrahidrokuilina sebagai antagonis glisilina
ID28811A (id) Antagonis reseptor vitronektin
ATE264301T1 (de) Muscarin-antagonisten
DE60114796D1 (de) Analgetisch wirksame benzosuberonylpiperidin-verbindungen
SI1140931T1 (en) 5ht1 antagonists for antidepressant therapy
ES1041026Y (es) Vibrador terapeutico.
SE9802023D0 (sv) New therapeutic use
SE9801099D0 (sv) New compounds
SE9803746D0 (sv) New compounds
SE9800977D0 (sv) New compounds
SE9800834D0 (sv) New Compounds
SE9800512D0 (sv) New compounds
SE9800511D0 (sv) New compounds
SE9800509D0 (sv) New Compounds